Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (OneStep-2)
Primary Purpose
Diabetic Foot Infection
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Topical pexiganan cream 0.8%
Topical placebo cream
Standard wound care
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Foot Infection focused on measuring Diabetic Foot Ulcer Infection
Eligibility Criteria
Inclusion Criteria:
- Diabetes mellitus.
- Male or female at least 18 years old.
- Subject must agree to adhere to all protocol procedures and return for all scheduled visits, and must be willing and able to provide written informed consent.
- Subject is to be treated on an outpatient basis.
- Full thickness ulcer or a partial thickness ulcer on the foot distal to the malleoli with a surface area ≥ 1 cm2 after the wound has undergone appropriate debridement.
- Localized mild infection of the ulcer.
- The diagnosis of mild infection must be confirmed immediately following debridement at Baseline.
- Subject must have plain radiographs taken within 2 days prior to entry showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.
Exclusion Criteria:
- IDSA-defined moderate infection, including cellulitis extending > 2 cm; lymphangitis; spread beneath the fascia; deep tissue abscess; gangrene; muscle, joint, or bone involvement.
- IDSA-defined severe infection, including systemic toxicity or metabolic instability.
- Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware.
- > 1 infected foot ulcer.
- Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
- Subject has received a systemic antibiotic within 48 hours prior to Screening.
- Concurrent or expected to require systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
- Bone or joint involvement is suspected based on clinical examination or plain X-ray.
- Clinically significant peripheral arterial disease requiring vascular intervention.
- Subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period, or is unable to safely monitor the infection status at home.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Topical placebo control
Topical pexiganan cream 0.8%
Arm Description
Drug: Topical placebo cream
Drug: Topical pexiganan cream 0.8%
Outcomes
Primary Outcome Measures
Number of Participants With Clinical Response
The numbers of participants with Clinical Response, defined as resolution of infection, are reported.
Secondary Outcome Measures
Number of Participants With Microbiological Response
The numbers of participants with Microbiological Response, defined are eradication of all baseline pathogens, are reported.
Number of Participants With Treatment-Emergent Adverse Events (TEAE)
The number of participants with TEAEs, including Serious TEAEs, are reported
Full Information
NCT ID
NCT01594762
First Posted
May 7, 2012
Last Updated
May 19, 2017
Sponsor
Dipexium Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01594762
Brief Title
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Acronym
OneStep-2
Official Title
A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dipexium Pharmaceuticals, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Infection
Keywords
Diabetic Foot Ulcer Infection
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Topical placebo control
Arm Type
Placebo Comparator
Arm Description
Drug: Topical placebo cream
Arm Title
Topical pexiganan cream 0.8%
Arm Type
Experimental
Arm Description
Drug: Topical pexiganan cream 0.8%
Intervention Type
Drug
Intervention Name(s)
Topical pexiganan cream 0.8%
Other Intervention Name(s)
MSI-78
Intervention Description
14 days of treatment
Intervention Type
Drug
Intervention Name(s)
Topical placebo cream
Intervention Description
14 days of treatment
Intervention Type
Other
Intervention Name(s)
Standard wound care
Intervention Description
14 days of treatment
Primary Outcome Measure Information:
Title
Number of Participants With Clinical Response
Description
The numbers of participants with Clinical Response, defined as resolution of infection, are reported.
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Number of Participants With Microbiological Response
Description
The numbers of participants with Microbiological Response, defined are eradication of all baseline pathogens, are reported.
Time Frame
28 days
Title
Number of Participants With Treatment-Emergent Adverse Events (TEAE)
Description
The number of participants with TEAEs, including Serious TEAEs, are reported
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diabetes mellitus.
Male or female at least 18 years old.
Subject must agree to adhere to all protocol procedures and return for all scheduled visits, and must be willing and able to provide written informed consent.
Subject is to be treated on an outpatient basis.
Full thickness ulcer or a partial thickness ulcer on the foot distal to the malleoli with a surface area ≥ 1 cm2 after the wound has undergone appropriate debridement.
Localized mild infection of the ulcer.
The diagnosis of mild infection must be confirmed immediately following debridement at Baseline.
Subject must have plain radiographs taken within 2 days prior to entry showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.
Exclusion Criteria:
IDSA-defined moderate infection, including cellulitis extending > 2 cm; lymphangitis; spread beneath the fascia; deep tissue abscess; gangrene; muscle, joint, or bone involvement.
IDSA-defined severe infection, including systemic toxicity or metabolic instability.
Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware.
> 1 infected foot ulcer.
Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
Subject has received a systemic antibiotic within 48 hours prior to Screening.
Concurrent or expected to require systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
Bone or joint involvement is suspected based on clinical examination or plain X-ray.
Clinically significant peripheral arterial disease requiring vascular intervention.
Subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period, or is unable to safely monitor the infection status at home.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael H. Silverman, MD
Organizational Affiliation
Biostrategics Consulting Ltd
Official's Role
Study Director
Facility Information:
City
Phoenix
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Jonesboro
State/Province
Arkansas
Country
United States
City
Castro Valley
State/Province
California
Country
United States
City
Davis
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Napa
State/Province
California
Country
United States
City
San Francisco
State/Province
California
Country
United States
City
Santa Rosa
State/Province
California
Country
United States
City
Sylmar
State/Province
California
Country
United States
City
Vacaville
State/Province
California
Country
United States
City
Norwalk
State/Province
Connecticut
Country
United States
City
Coral Gables
State/Province
Florida
Country
United States
City
Doral
State/Province
Florida
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Homestead
State/Province
Florida
Country
United States
City
Jacksonville
State/Province
Florida
Country
United States
City
Largo
State/Province
Florida
Country
United States
City
Miami Lakes
State/Province
Florida
Country
United States
City
Miami Shores
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Pinellas Park
State/Province
Florida
Country
United States
City
Evans
State/Province
Georgia
Country
United States
City
North Chicago
State/Province
Illinois
Country
United States
City
Hutchinson
State/Province
Kansas
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Mineola
State/Province
New York
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Wilmington
State/Province
North Carolina
Country
United States
City
Duncansville
State/Province
Pennsylvania
Country
United States
City
York
State/Province
Pennsylvania
Country
United States
City
Columbia
State/Province
South Carolina
Country
United States
City
El Paso
State/Province
Texas
Country
United States
City
Fort Worth
State/Province
Texas
Country
United States
City
Lewisville
State/Province
Texas
Country
United States
City
Saint George
State/Province
Utah
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
Roanoke
State/Province
Virginia
Country
United States
City
Richland
State/Province
Washington
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
We'll reach out to this number within 24 hrs